Ipamorelin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
Ipamorelin is the cleanest growth-hormone secretagogue we have. It is a five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) engineered in the late 1990s to do one specific thing: tap the ghrelin receptor on your pituitary and prompt a pulse of your own growth hormone — without the collateral hormone noise that plagued the earlier secretagogues.
Here is the framing that matters. Ipamorelin does not inject GH into you. It asks your pituitary to release the GH you already make, in the natural pulses your body is built around. That is a fundamentally different — and more physiologic — approach than exogenous HGH, which floods the system with a non-pulsatile signal your body never sees naturally. As one practitioner puts it in his masterclass, secretagogues like ipamorelin “restore declining endogenous growth-hormone signaling rather than replace it”.
It is most famous as half of the CJC-1295 + Ipamorelin blend (see CJC-1295 / Ipamorelin), where it supplies the ghrelin-pathway pulse while CJC-1295 supplies the GHRH-pathway baseline. But it stands on its own as a single agent too.
What does it do in my body?
Your body releases growth hormone in pulses, mostly during deep sleep and after hard exercise. Two upstream signals drive those pulses: GHRH (growth-hormone-releasing hormone — the lever Sermorelin and CJC-1295 pull) and ghrelin, the gut peptide better known as the “hunger hormone.” Ghrelin is also a powerful, independent GH stimulator working through its own receptor, GHS-R1a. Ipamorelin is a selective mimic of that ghrelin action — it binds GHS-R1a on the pituitary and triggers a GH pulse, running on a parallel track to the GHRH system.
The defining feature is selectivity. The earlier ghrelin-mimics (GHRP-6, GHRP-2) also spiked cortisol — your stress hormone — and prolactin. Ipamorelin doesn’t. In pigs and rat pituitary cells, it released GH without touching cortisol, ACTH, prolactin, or thyroid even at more than 200 times the GH-effective dose. That is the whole engineering achievement: a pure GH signal with no stress-hormone splash. One practitioner cites a “2004 Journal of Endocrinology” paper for the same point — GH release “with minimal effects on prolactin and cortisol” — but on verification that selectivity finding traces to the foundational Raun 1998 Eur J Endocrinol paper [PMID 9849822]; there is no separate 2004 paper behind it, so we cite the real source.
Because it hits a different receptor than GHRH analogs, ipamorelin pairs naturally with one. Stimulate GHS-R1a and the GHRH receptor at the same time and the pituitary — which expresses both — puts out a bigger pulse than either signal alone. One practitioner cites a “2018 European Journal of Endocrinology” study for combined GHRH + ghrelin-agonist GH secretion exceeding either alone. That specific cite doesn’t resolve, but the underlying synergy is real and verified: Hataya et al. 2001 (JCEM) showed a low dose of ghrelin stimulates GH release synergistically with GHRH in humans. One practitioner’s “~40% greater GH elevation” figure is his own framing and isn’t a number from that literature. That dual-receptor synergy is the entire rationale for the blend.
How can it help me?
The selective, clean-signal growth-hormone secretagogue. A pentapeptide that flips the ghrelin switch on your pituitary to release a pulse of your own GH — without dragging cortisol or prolactin along for the ride. The most-used GH peptide in the wellness world, and the rationale for the famous CJC-1295 + Ipamorelin blend.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Ipamorelin is one of the better-tolerated peptides in this category, and the data backs that up rather than just the marketing.
What the trial showed: In the Beck 2014 RCT, adverse events were actually slightly lower on ipamorelin than on placebo — it was genuinely well tolerated short-term [PMID 25331030].
What users report:
- A brief hunger spike shortly after injection — expected, since it’s a ghrelin mimic. Usually mild and fades within an hour.
- Transient flushing, mild headache, occasional lightheadedness.
- Mild water retention if GH signaling is pushed too hard — one practitioner’s practical fix is to dial the dose back until it disappears.
- Injection-site irritation, typically minor and self-limiting.
Most of these resolve in 30–60 minutes and are dose-related — smaller, well-timed doses minimize them.
The longer-term considerations, stated plainly: Anything that raises GH/IGF-1 is worth using thoughtfully. The sensible move is to keep elevation in the physiologic range (one practitioner frames the target as ~2–3× normal GH/IGF-1, not the supraphysiologic flood of exogenous HGH) and to check IGF-1 against your age-adjusted range periodically if you run it long-term. One practitioner’s broader thesis is that secretagogues are safer than exogenous HGH precisely because they preserve pulsatility and your body’s own somatostatin brake — you can’t blow past the ceiling the way raw injected GH can. On the cancer question specifically, he rebuts the “GH causes cancer” fear. His own “2004 JCEM ~6,200-patient” cite doesn’t resolve, but the real, stronger evidence backs the point: a 2016 meta-analysis (9 studies, 11,191 participants) found GH-replacement therapy in GH-deficient adults was associated with reduced cancer risk (RR 0.69), and the large SAGhE European cohort found no clear excess cancer risk in patients without other major disease. The standard conservative move is still to avoid use with active cancer; long-term human safety data for ipamorelin specifically does not yet exist. That’s a known gap, stated honestly — not a reason for alarm.
Regulatory status: Ipamorelin is not FDA-approved. It originated as an investigational compound (a Novo Nordisk program) that was studied through Phase 2 and not carried further. In 2023 it was placed on the FDA’s 503A Category 2 bulk-substances list, which restricts compounding-pharmacy access and pushes sourcing toward research-chemical vendors. It is prohibited by WADA in sport. Everything sold today is research-use-only.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
The exact bacteriostatic-water volume and resulting concentration for Ipamorelin are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
This is the protocol the peptide community and practitioners have converged on, drawn from a commonly used practitioner protocol and consistent with how ipamorelin is run in practice.
Standard solo protocol:
- Dose: 300 mcg, AM and PM
- Schedule: 5 days on / 2 days off
- Cycle: 8 weeks on, then off
- Reconstitution: 10 mg vial + 3 ml bacteriostatic water = 3,333 mcg/ml. A 300 mcg dose = 0.09 ml = 9 units on a standard 100-unit (U-100) insulin syringe.
Timing: Most people dose at night and/or fasted, to ride the natural overnight GH pulse — ipamorelin’s short half-life makes it well suited to a “tap the pulse” approach rather than continuous signaling. Food (especially carbs/fat) near the dose blunts the GH response, which is why fasted dosing is the convention.
Cycling: The community default is 5-on/2-off within an 8-week block, then a break, to keep the ghrelin receptor responsive and avoid desensitization. One practitioner’s general cycling rule: cycle the GH-axis peptides rather than running them indefinitely.
What should I avoid combining — and what's synergistic?
Stacking — the blend: The most common use is alongside CJC-1295 (no-DAC) in the CJC-1295 / Ipamorelin blend, at 250 mcg / 250 mcg per dose, AM/PM, same 5-on/2-off, 8-week structure. The rationale is dual-receptor synergy (above). Alyve sells this pre-blended (in stock, COA 99.90%).
Where experts differ: one practitioner’s masterclass argues for pairing ipamorelin with CJC-1295 with-DAC (once-weekly) rather than no-DAC daily, on the grounds that DAC gives more consistent IGF-1 and slower tachyphylaxis. The community cheat-sheet convention runs the no-DAC daily blend. Both are valid; the no-DAC blend is what Alyve stocks and what most people start with. One practitioner also flags that pairing a longer-baseline secretagogue (e.g. MK-677, a non-peptide oral ghrelin agonist) with short-acting ipamorelin gives “both pulsatile spikes AND long-term baseline elevation” — a more advanced stack.
How can I buy this?
Alyve lists Ipamorelin standalone at $34.00–$64.99 (5 mg / 10 mg), currently showing out of stock — and there is no standalone COA captured on disk yet for the solo SKU.
The route that is in stock and verified is the CJC-1295 + Ipamorelin Blend (5 mg / 5 mg), $68.00 (on sale from $78.00), tested at 99.90% purity by Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity, lot CJI583). That is genuinely high-purity, identity-confirmed product — which matters more than most buyers realize. Essentially all peptide raw material is sorted into stringency tiers, and the gray market is batch-to-batch unknown; a third-party COA at >99% is the verified-clean tier. The blend is covered fully in CJC-1295 / Ipamorelin.
Offer: Use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 also attributes the sale to me — I’d rather tell you than hide it.)
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
The selective, clean-signal growth-hormone secretagogue. A pentapeptide that flips the ghrelin switch on your pituitary to release a pulse of your own GH — without dragging cortisol or prolactin along for the ride. The most-used GH peptide in the wellness world, and the rationale for the famous CJC-1295 + Ipamorelin blend.
| Class | Growth hormone secretagogue (GHS) — selective ghrelin-receptor (GHS-R1a) agonist; a pentapeptide |
| Mechanism (one-liner) | Mimics ghrelin at the pituitary to trigger a clean pulse of your own GH — no cortisol/prolactin splash |
| Route | Subcutaneous injection (the community standard); IV was used in the lone formal trial |
| Half-life | ~2 hours |
| Evidence | Selectivity proven in animal/in-vitro [PMID 9849822]; human PK confirmed [PMID 26811125, 10496658]; one human ileus RCT [PMID 25331030]; GHRH+ghrelin synergy in humans [PMID 11549707]; wide practitioner use |
| Regulatory status | Not FDA-approved. On the FDA 503A Category 2 bulk list (2023). WADA-prohibited in sport. |
| Alyve product | Standalone Ipamorelin, $34.00–$64.99 (currently out of stock); also in the in-stock CJC-1295 + Ipamorelin blend (COA 99.90%) |
| Primary OHM use case | The ghrelin-pathway “pulse trigger” people run for sleep, recovery, and body composition — solo or stacked with CJC-1295 |
What it is
Ipamorelin is the cleanest growth-hormone secretagogue we have. It is a five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) engineered in the late 1990s to do one specific thing: tap the ghrelin receptor on your pituitary and prompt a pulse of your own growth hormone — without the collateral hormone noise that plagued the earlier secretagogues.
Here is the framing that matters. Ipamorelin does not inject GH into you. It asks your pituitary to release the GH you already make, in the natural pulses your body is built around. That is a fundamentally different — and more physiologic — approach than exogenous HGH, which floods the system with a non-pulsatile signal your body never sees naturally. As one practitioner puts it in his masterclass, secretagogues like ipamorelin “restore declining endogenous growth-hormone signaling rather than replace it”.
It is most famous as half of the CJC-1295 + Ipamorelin blend (see CJC-1295 / Ipamorelin), where it supplies the ghrelin-pathway pulse while CJC-1295 supplies the GHRH-pathway baseline. But it stands on its own as a single agent too.
How it works
Your body releases growth hormone in pulses, mostly during deep sleep and after hard exercise. Two upstream signals drive those pulses: GHRH (growth-hormone-releasing hormone — the lever Sermorelin and CJC-1295 pull) and ghrelin, the gut peptide better known as the “hunger hormone.” Ghrelin is also a powerful, independent GH stimulator working through its own receptor, GHS-R1a. Ipamorelin is a selective mimic of that ghrelin action — it binds GHS-R1a on the pituitary and triggers a GH pulse, running on a parallel track to the GHRH system.
The defining feature is selectivity. The earlier ghrelin-mimics (GHRP-6, GHRP-2) also spiked cortisol — your stress hormone — and prolactin. Ipamorelin doesn’t. In pigs and rat pituitary cells, it released GH without touching cortisol, ACTH, prolactin, or thyroid even at more than 200 times the GH-effective dose. That is the whole engineering achievement: a pure GH signal with no stress-hormone splash. One practitioner cites a “2004 Journal of Endocrinology” paper for the same point — GH release “with minimal effects on prolactin and cortisol” — but on verification that selectivity finding traces to the foundational Raun 1998 Eur J Endocrinol paper [PMID 9849822]; there is no separate 2004 paper behind it, so we cite the real source.
Because it hits a different receptor than GHRH analogs, ipamorelin pairs naturally with one. Stimulate GHS-R1a and the GHRH receptor at the same time and the pituitary — which expresses both — puts out a bigger pulse than either signal alone. One practitioner cites a “2018 European Journal of Endocrinology” study for combined GHRH + ghrelin-agonist GH secretion exceeding either alone. That specific cite doesn’t resolve, but the underlying synergy is real and verified: Hataya et al. 2001 (JCEM) showed a low dose of ghrelin stimulates GH release synergistically with GHRH in humans. One practitioner’s “~40% greater GH elevation” figure is his own framing and isn’t a number from that literature. That dual-receptor synergy is the entire rationale for the blend.
What the research shows
Here is the full picture, every tier labeled, strongest findings first.
Selectivity & mechanism — the foundation. The original Raun 1998 work is the bedrock: ipamorelin releases GH cleanly and dose-dependently while leaving cortisol, prolactin, ACTH, and thyroid untouched [PMID 9849822]. This is the most-cited, best-replicated thing about the molecule, and it is what makes ipamorelin the “clean” secretagogue.
Human pharmacokinetics. Intact ipamorelin and its active metabolites were confirmed in human urine after dosing — so it is real, absorbed, and biologically present in people [PMID 26811125].
The human ileus trial. Beck et al. 2014 ran a multicenter, double-blind, placebo-controlled Phase 2 trial (n=114) testing IV ipamorelin for post-operative ileus — sluggish gut after bowel surgery. Time-to-first-meal was faster on ipamorelin (25.3 h vs 32.6 h) but the difference did not reach statistical significance (p=0.15), and the program was not advanced past Phase 2 [PMID 25331030]. Read that finding as information, not a verdict on the molecule: this was a single trial of an IV gut-motility indication, dosed by body weight — a completely different use, route, and dose from the subcutaneous GH-axis microdosing people actually run. It tells you almost nothing about ipamorelin for sleep, recovery, or body composition, because that is not what it measured. What it does tell you is that ipamorelin was well tolerated in humans (see Side effects).
Preclinical efficacy. This is where the GH-axis benefit signal lives, and it is substantial:
- Counteracted glucocorticoid-induced bone and muscle loss in rats [PMID 11735244].
- Accelerated gut motility in rodent ileus models [PMID 19289567, 27186127].
- Blunted chemotherapy-induced weight loss in ferrets [PMID 39043357].
The body-composition story is mechanistic and animal-derived — and that is exactly where a bleeding-edge GH peptide sits. The downstream logic one practitioner lays out (restored GH → IGF-1 → muscle protein synthesis, mitochondrial biogenesis, fat mobilization, better recovery) is built on GH/IGF-1 physiology, not yet on a positive human body-comp RCT of ipamorelin specifically. The honest read: the mechanism is well-mapped, the selectivity is proven in the lab, the human safety looks clean short-term, and the body-composition outcomes are extrapolated from GH biology plus the wide real-world use base. That is the current state of the science — not a reason it doesn’t work, but a transparent map of what’s behind each claim.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
This is the protocol the peptide community and practitioners have converged on, drawn from a commonly used practitioner protocol and consistent with how ipamorelin is run in practice.
Standard solo protocol:
- Dose: 300 mcg, AM and PM
- Schedule: 5 days on / 2 days off
- Cycle: 8 weeks on, then off
- Reconstitution: 10 mg vial + 3 ml bacteriostatic water = 3,333 mcg/ml. A 300 mcg dose = 0.09 ml = 9 units on a standard 100-unit (U-100) insulin syringe.
Timing: Most people dose at night and/or fasted, to ride the natural overnight GH pulse — ipamorelin’s short half-life makes it well suited to a “tap the pulse” approach rather than continuous signaling. Food (especially carbs/fat) near the dose blunts the GH response, which is why fasted dosing is the convention.
Stacking — the blend: The most common use is alongside CJC-1295 (no-DAC) in the CJC-1295 / Ipamorelin blend, at 250 mcg / 250 mcg per dose, AM/PM, same 5-on/2-off, 8-week structure. The rationale is dual-receptor synergy (above). Alyve sells this pre-blended (in stock, COA 99.90%).
Where experts differ: one practitioner’s masterclass argues for pairing ipamorelin with CJC-1295 with-DAC (once-weekly) rather than no-DAC daily, on the grounds that DAC gives more consistent IGF-1 and slower tachyphylaxis. The community cheat-sheet convention runs the no-DAC daily blend. Both are valid; the no-DAC blend is what Alyve stocks and what most people start with. One practitioner also flags that pairing a longer-baseline secretagogue (e.g. MK-677, a non-peptide oral ghrelin agonist) with short-acting ipamorelin gives “both pulsatile spikes AND long-term baseline elevation” — a more advanced stack.
Cycling: The community default is 5-on/2-off within an 8-week block, then a break, to keep the ghrelin receptor responsive and avoid desensitization. One practitioner’s general cycling rule: cycle the GH-axis peptides rather than running them indefinitely.
Side effects & management
Ipamorelin is one of the better-tolerated peptides in this category, and the data backs that up rather than just the marketing.
What the trial showed: In the Beck 2014 RCT, adverse events were actually slightly lower on ipamorelin than on placebo — it was genuinely well tolerated short-term [PMID 25331030].
What users report:
- A brief hunger spike shortly after injection — expected, since it’s a ghrelin mimic. Usually mild and fades within an hour.
- Transient flushing, mild headache, occasional lightheadedness.
- Mild water retention if GH signaling is pushed too hard — one practitioner’s practical fix is to dial the dose back until it disappears.
- Injection-site irritation, typically minor and self-limiting.
Most of these resolve in 30–60 minutes and are dose-related — smaller, well-timed doses minimize them.
The longer-term considerations, stated plainly: Anything that raises GH/IGF-1 is worth using thoughtfully. The sensible move is to keep elevation in the physiologic range (one practitioner frames the target as ~2–3× normal GH/IGF-1, not the supraphysiologic flood of exogenous HGH) and to check IGF-1 against your age-adjusted range periodically if you run it long-term. One practitioner’s broader thesis is that secretagogues are safer than exogenous HGH precisely because they preserve pulsatility and your body’s own somatostatin brake — you can’t blow past the ceiling the way raw injected GH can. On the cancer question specifically, he rebuts the “GH causes cancer” fear. His own “2004 JCEM ~6,200-patient” cite doesn’t resolve, but the real, stronger evidence backs the point: a 2016 meta-analysis (9 studies, 11,191 participants) found GH-replacement therapy in GH-deficient adults was associated with reduced cancer risk (RR 0.69), and the large SAGhE European cohort found no clear excess cancer risk in patients without other major disease. The standard conservative move is still to avoid use with active cancer; long-term human safety data for ipamorelin specifically does not yet exist. That’s a known gap, stated honestly — not a reason for alarm.
Regulatory status
Ipamorelin is not FDA-approved. It originated as an investigational compound (a Novo Nordisk program) that was studied through Phase 2 and not carried further. In 2023 it was placed on the FDA’s 503A Category 2 bulk-substances list, which restricts compounding-pharmacy access and pushes sourcing toward research-chemical vendors. It is prohibited by WADA in sport. Everything sold today is research-use-only.
The Alyve product
Alyve lists Ipamorelin standalone at $34.00–$64.99 (5 mg / 10 mg), currently showing out of stock — and there is no standalone COA captured on disk yet for the solo SKU.
The route that is in stock and verified is the CJC-1295 + Ipamorelin Blend (5 mg / 5 mg), $68.00 (on sale from $78.00), tested at 99.90% purity by Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity, lot CJI583). That is genuinely high-purity, identity-confirmed product — which matters more than most buyers realize. Essentially all peptide raw material is sorted into stringency tiers, and the gray market is batch-to-batch unknown; a third-party COA at >99% is the verified-clean tier. The blend is covered fully in CJC-1295 / Ipamorelin.
Offer: Use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 also attributes the sale to me — I’d rather tell you than hide it.)
Sources
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. : 9849822
- Beck DE, et al. Ghrelin mimetic ipamorelin for postoperative ileus — Phase 2 RCT. Int J Colorectal Dis. 2014. : 25331030
- Andersen NB, et al. Ipamorelin counteracts glucocorticoid-induced bone/muscle loss (rat). Growth Horm IGF Res. 2001. : 11735244
- Venkova K, et al. Ipamorelin in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009. : 19289567
- Greenwood-Van Meerveld B, et al. Ipamorelin on gastric dysmotility (rat). J Exp Pharmacol. 2012. : 27186127
- Lu Z, et al. Anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets. Physiol Behav. 2024. : 39043357
- Ferro P, et al. Structure-activity relationship for peptidic GH secretagogues (human excretion). Drug Test Anal. 2017. : 26811125
- Hataya Y, et al. Low dose of ghrelin stimulates GH release synergistically with GHRH in humans. J Clin Endocrinol Metab. 2001. : 11549707
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (terminal t½ 2 h; GH peak ~0.67 h). Pharm Res. 1999;16:1412–1416. : 10496658
- Li Z, et al. GH replacement therapy reduces risk of cancer in adults with GH deficiency — meta-analysis (9 studies, 11,191 participants; RR 0.69). Oncotarget. 2016. : 27835910
- Swerdlow AJ, et al. Cancer risks in patients treated with GH in childhood (SAGhE European cohort). J Clin Endocrinol Metab. 2017. : 28184422
- Video digest — one practitioner CJC-1295/Ipamorelin Masterclass.
- Dosing/reconstitution cheat sheet (one practitioner).
- Alyve COA summary (blend 99.90%, lot CJI583).
- Alyve Peptides — Ipamorelin product page. / https://alyvepeptides.com/product/ipamorelin/
See also: CJC-1295, Sermorelin, CJC-1295 / Ipamorelin, Tesamorelin.